Package Leaflet: Information for the User
Maviret 100mg/40mg film-coated tablets
glecaprevir/pibrentasvir
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack
Maviret is an antiviral medicine used to treat adults and children (from 3 years of age) with long-term (chronic) hepatitis C infection. This is an infectious disease that affects the liver and is caused by the hepatitis C virus. Maviret contains the active substances glecaprevir and pibrentasvir.
Maviret works by preventing the hepatitis C virus from multiplying and infecting new cells. This eliminates the infection from the body.
Do not take Maviret:
Do not take Maviret if you are in any of the above situations. If in doubt, consult your doctor or pharmacist before taking Maviret.
Warnings and precautions
Tell your doctor if you are in any of the following situations, as you may need closer monitoring:
Blood tests
Your doctor will perform blood tests before, during and after treatment with Maviret. This will help determine:
Children
This medicine must not be given to children under 3 years of age or weighing less than 12 kg. The use of Maviret in children under 3 years of age or weighing less than 12 kg has not been studied yet.
Other medicines and Maviret
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Tell your doctor or pharmacistbefore taking Maviret if you are taking any of the medicines listed in the following table. Your doctor may need to change the dose of these medicines.
Medicines that you should tell your doctor about before taking Maviret | |
Medicine | Purpose of the medicine |
ciclosporin, tacrolimus | to reduce the activity of the immune system |
darunavir, efavirenz, lopinavir, ritonavir | for HIV infection |
digoxin | for heart problems |
fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin | to lower blood cholesterol |
warfarin and other similar medicines* | to prevent blood clots |
If you are in any of the above situations (or are unsure), consult your doctor or pharmacist before taking Maviret.
Pregnancy and contraception
The effects of Maviret during pregnancy are not known. If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine, as it is not recommended to take Maviret during pregnancy. Contraceptive medicines containing ethinylestradiol must not be used in combination with Maviret.
Breast-feeding
Ask your doctor or pharmacist for advice before taking Maviret if you are breast-feeding. It is not known if the active substances in Maviret pass into breast milk.
Driving and using machines
Maviret is unlikely to affect your ability to drive or use tools or machines.
Maviret contains lactose
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.
Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. Your doctor will tell you how long you need to take Maviret.
Maviret tablets are for adults, children from 12 years of age, or children weighing 45 kg or more. Maviret granules are for children from 3 years of age to less than 12 years and weighing 12 kg to less than 45 kg.
How much to take
The recommended dose for adults, children from 12 years of age, or children weighing at least 45 kg is three Maviret 100 mg/40 mg tablets taken together, once a day. The daily dose is the three tablets from one blister.
How to take the medicine
If you vomit after taking Maviret, the amount of this medicine in your blood may be affected. In this case, the effectiveness of Maviret may be lower.
If you take more Maviret than you should
If you accidentally take a higher dose than recommended, consult your doctor or go to the nearest hospital immediately. Take the medicine pack with you to show the doctor what you have taken.
If you forget to take Maviret
It is important not to miss any doses of this medicine.
If you forget to take a dose, calculate how long it has been since you should have taken Maviret:
If you have any further questions on the use of this product, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Tell your doctor or pharmacist if you notice any of the following side effects:
Very common:may affect more than 1 in 10 people
Common:may affect up to 1 in 10 people
Uncommon:may affect up to 1 in 100 people
Frequency not known:cannot be estimated from the available data
Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in the Yellow Card Scheme: www.mhra.gov.uk/yellowcard. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton after “EXP” and on the blister after “EXP”. The expiry date refers to the last day of the month shown.
This medicine does not require any special storage conditions.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.
What Maviret contains
Maviret contains lactose and sodium. See section 2.
Appearance and packaging
Maviret tablets are pink, oval, biconvex, film-coated tablets, 18.8 mm x 10.0 mm in size, marked with “NXT” on one side.
Maviret tablets are packaged in blisters containing 3 tablets each. Maviret is available in packs of 84 tablets, with 4 boxes, each containing 21 film-coated tablets.
Marketing Authorisation Holder
AbbVie Deutschland GmbH & Co. KG
Knollstrasse
67061 Ludwigshafen
Germany
Manufacturer
AbbVie Deutschland GmbH & Co. KG
Knollstrasse
67061 Ludwigshafen
Germany
or
AbbVie Logistics B.V
Zuiderzeelaan 53
8017 JV Zwolle
Netherlands
For further information about this medicine, contact the local representative of the Marketing Authorisation Holder:
België/Belgique/Belgien AbbVie SA Tél/Tel: +32 10 477811 | Lietuva AbbVie UAB Tel: +370 5 205 3023 |
???????? ???? ???? ???.: +359 2 90 30 430 | Luxembourg/Luxemburg AbbVie SA Belgique/Belgien Tél/Tel: +32 10 477811 |
Ceská republika AbbVie s.r.o. Tel: +420 233 098 111 | Magyarország AbbVie Kft. Tel.: +36 1 455 8600 |
Danmark AbbVie A/S Tlf: +45 72 30‑20‑28 | Malta V.J.Salomone Pharma Limited Tel: +356 22983201 |
Deutschland AbbVie Deutschland GmbH & Co. KG Tel: 00800 222843 33 (gebührenfrei) Tel: +49 (0) 611 / 1720‑0 | Nederland AbbVie B.V. Tel: +31 (0)88 322 2843 |
Eesti AbbVie OÜ Tel: +372 623 1011 | Norge AbbVie AS Tlf: +47 67 81 80 00 |
Ελλ?δα AbbVie ΦΑΡΜΑΚΕΥΤΙΚΗ Α.Ε. Τηλ: +30 214 4165 555 | Österreich AbbVie GmbH Tel: +43 1 20589‑0 |
España AbbVie Spain, S.L.U. Tel: +34 91 384 09 10 | Polska AbbVie Polska Sp. z o.o. Tel.: +48 22 372 78 00 |
France AbbVie Tél: +33 (0)1 45 60 13 00 | Portugal AbbVie, Lda. Tel: +351 (0)21 1908400 |
Hrvatska AbbVie d.o.o. Tel: +385 (0)1 5625 501 | România AbbVie S.R.L. Tel: +40 21 529 30 35 |
Ireland AbbVie Limited Tel: +353 (0)1 4287900 | Slovenija AbbVie Biofarmacevtska družba d.o.o. Tel: +386 (1)32 08 060 |
Ísland Vistor hf. Sími: +354 535 7000 | Slovenská republika AbbVie s.r.o. Tel: +421 2 5050 0777 |
Italia AbbVie S.r.l. Tel: +39 06 928921 | Suomi/Finland AbbVie Oy Puh/Tel: +358 (0)10 2411 200 |
Κ?προς Lifepharma (Z.A.M.) Ltd Τηλ: +357 22 34 74 40 | Sverige AbbVie AB Tel: +46 (0)8 684 44 600 |
Latvija AbbVie SIA Tel: +371 67605000 | United Kingdom (Northern Ireland) AbbVie Deutschland GmbH & Co. KG Tel: +44 (0)1628 561090 |
Date of last revision of this leaflet: 05/2022
Other sources of information
Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu.
To request a copy of this leaflet in large print, contact the local representative of the Marketing Authorisation Holder.